![]() |
|
|
Vol. 29, Issue 5, 664-675, May 2001
Faculty of Pharmaceutical Sciences (H.W., S.K., E.K., F.S.A.,
K.W.R.) and British Columbia Research Institute for Children's and
Women's Health, Department of Obstetrics and Gynecology, Faculty of
Medicine (D.W.R.), The University of British Columbia, Vancouver,
British Columbia, Canada
Dose-dependent pharmacokinetics and metabolism of valproic acid
(VPA) were studied in newborn and adult sheep to assess age-related differences in plasma protein binding and metabolic elimination. Newborn lambs received either a 10- (n = 8), 50- (n = 5), 100- (n = 4), or
250-mg/kg (n = 4) VPA i.v. bolus.
Individual adult sheep (n = 5) received all four
doses in a random order with an appropriate washout period between
experiments. Unbound or metabolic clearance of VPA was significantly
higher in adult sheep at the two lower doses when compared with lambs,
and similar to the lambs at the two higher doses. Plasma protein
binding was nonlinear at all doses. Estimates of binding capacity
(Bmax1) at the saturable site were higher in
adults (91.8 µg/ml) when compared with lambs (44.9 µg/ml), whereas
the opposite trend was observed for binding affinity
[Kd1 = 9.6 µg/ml (adult) versus 3.2 µg/ml (lambs)]. Characterization of developmental differences in
overall VPA metabolic elimination involved fitting of unbound VPA
plasma concentration data to a two-compartment model with
Michaelis-Menten elimination. This resulted in similar in vivo
estimates of apparent Vmax [445.0 µg/min/kg (adult) versus 429.9 µg/min/kg (lambs)]. However,
apparent Km estimates appeared to be higher
in lambs [30.0 µg/ml (adult) versus 69.6 µg/ml (lambs)]. Similar
findings were obtained from in vivo estimates of
Vmax and Km for
VPA glucuronidation obtained from VPA-glucuronide metabolite urinary
excretion data. Thus, it appears that age-related differences in
metabolic clearance may be related to differences in the apparent in
vivo Km as opposed to
Vmax of VPA glucuronidation.
This article has been cited by other articles:
![]() |
H. Wong, V. Tong, K. W. Riggs, D. W. Rurak, F. S. Abbott, and S. Kumar Kinetics of Valproic Acid Glucuronidation: Evidence for in Vivo Autoactivation Drug Metab. Dispos., August 1, 2007; 35(8): 1380 - 1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Achachi, A. Florins, N. Gillet, C. Debacq, P. Urbain, G. M. Foutsop, F. Vandermeers, A. Jasik, M. Reichert, P. Kerkhofs, et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo PNAS, July 19, 2005; 102(29): 10309 - 10314. [Abstract] [Full Text] [PDF] |
||||